ClinicalTrials.gg
TerminatedNCT05643573OCEANIC-AFUpdated Dec 9, 2024Results posted

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

A Phase 3 interventional study of Asundexian (BAY2433334) and Apixaban in Prevention of Stroke or Systemic Embolism and Atrial Fibrillation, sponsored by Bayer. Terminated at 1,069 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Independent Data Monitoring Committee (IDMC) recommendation to stop the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14,830
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies in Atrial Fibrillation by Bayer — 1 open to participants now, 1 under way, none of them phase 3. Atrial Fibrillation · Bayer.

Enrollment
Largest of 13
14,830 · median 100
Started
2022
with 2 others
Phase 3
4 of 64
none open now
Registered
63rd of 64
by date

Among the 64 studies in Atrial Fibrillation by Bayer, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 63rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

1 of the 64 studies in Atrial Fibrillation by Bayer is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Atrial Fibrillation by Bayer, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel).

Atrial fibrillation is a condition of having irregular and often rapid heartbeat. It can lead to the formation of blood clots in the heart which can travel through the blood stream to plug another vessel, and like this lead to serious and life-threatening conditions, such as a stroke. A stroke occurs because the brain tissue beyond the blockage no longer receives nutrients and oxygen so that brain cells die. As strokes arising from atrial fibrillation can involve extensive areas of the brain, it is important to prevent them.

Blood clots are formed in a process known as coagulation. Medications are already available to prevent the formation of blood clots. When taken by mouth (orally), they are known as oral anticoagulants (OACs) including apixaban. OACs decrease the risk of the above-mentioned serious and life-threatening conditions. The main side effect of OACs is an increase of the risk of bleeding.

The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care with regard to the risk of bleeding.

The main purpose of this study is to collect more data about how well asundexian works to prevent stroke and systemic embolism and how safe it is compared to apixaban in people with atrial fibrillation and at high risk for stroke.

To see how well the study treatment asundexian works researchers compare:

  • how long asundexian works well and
  • how long apixaban works well after the start of the treatment. Working well means that the treatments can prevent the following from happening:
  • stroke and/or
  • systemic embolism. The study will keep collecting data until a certain number of strokes or embolisms happen in the study.

To see how safe asundexian is, the researchers will compare how often major bleedings occur after taking the study treatments asundexian and apixaban, respectively. Major bleedings are bleedings that have a serious or even life-threatening impact on a person's health.

The study participants will be randomly (by chance) assigned to 1 of 2 treatment groups, A and B. Dependent on the treatment group, the participants will either take the study treatment asundexian by mouth once a day or apixaban by mouth twice a day for approximately 9 - 33 months.

Each participant will be in the study for approximately 9 - 34 months. There will be visits to the study site every 3 to 6 months and up to 7 phone calls. Those participants who do not want or are unable to have visits to the study site may join the study remotely in selected locations. The location name contains the abbreviation - DCT in such cases.

During the study, the study team will:

  • take blood samples
  • do physical examinations
  • examine heart health using an electrocardiogram (ECG)
  • check vital signs such as blood pressure and heart rate
  • do pregnancy tests
  • ask the participants questions about their quality of life
  • ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

03

Conditions studied

  • Prevention of Stroke or Systemic Embolism
  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • The patient willing and able to understand the Patient information Sheet and provide written
  • Atrial fibrillation with an indication for indefinite treatment with an oral anticoagulant
  • CHA2DS2-VASc score ≥ 3 if male or ≥ 4 if female, OR CHA2DS2-VASc score of 2 if male or 3 if female and at least one of the following enrichment criteria:

    • age ≥ 70
    • previous stroke, , or systemic embolism
    • renal dysfunction with \< 50 ml/min within 14 days prior to randomization
    • prior episode of non-traumatic major bleeding
    • current single agent antiplatelet therapy planned to continue for at least 6 months after randomization
    • ≤ 6 consecutive weeks of treatment with oral anticoagulant prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Mechanical heart valve prosthesis
  • Moderate-to-severe mitral stenosis at the time of study inclusion.
  • Atrial fibrillation only due to reversible cause.
  • Participants after successful ablation therapy without documented recurrent AF or participants after left atrial appendage occlusion / exclusion or plan for ablation or Left atrial appendage (LAA) occlusion / exclusion within the next 6 months.
  • Recent ischemic stroke (within 7 days prior to randomization).
  • Active non-trivial bleeding; known chronic bleeding disorder ; history of non-traumatic intracranial hemorrhage.
  • Known significant liver disease or known hepatic insufficiency classified as B or C at randomization.
  • Estimated (eGFR) \< 25 mL/min/1.73 m2 within 14 days prior to randomization or on dialysis or expected to be started on dialysis within the next 12 months starting from randomization.
  • Major surgery during the last 30 days prior to randomization.
  • Known allergy, intolerance or to either of the study interventions.
  • Any for the use of an anticoagulant or listed in the local labelling for apixaban.
  • Requirement for chronic anticoagulation for a different indication than AF, e.g. mechanical heart valve or left ventricular cardiac thrombus (atrial thrombus is allowed), or dual antiplatelet therapy (single agent therapy is allowed).
  • Treatment with Vitamin K antagonist (VKA) in the 10 days prior to randomization.
  • Concomitant use of or anticipated need for:

    • daily or near daily (> 5 days per week) therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) for more than 4 weeks during the study
    • herbal or traditional medicine, and / or supplements with known anticoagulant and / or antiplatelet effect
    • combined P-glycoprotein (P-gp) and strong cytochrome P450 isoenzyme 3A4 () inhibitors
    • combined P-gp and strong / moderate CYP3A4 inducers Respective substances (apart from NSAIDs) must be stopped - in case of combined inhibitors / inducers of CYP3A4 and P-gp for at least 14 days before randomization.
  • Previous (within 30 days or 5 half-lives of the drug, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s). Registries and observational studies are allowed.
  • Known current alcohol and / or illicit drug abuse.
  • Close affiliation with the investigational site.
  • Any other history, condition or therapy, or uncontrolled intercurrent illness which would make the participant unsuitable for the study vulnerable or \< 12 months.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14,830 participants (actual)

Study arms

  • Experimental
    Asundexian

    Participants will receive asundexian and apixaban matching placebo.

    Drug: Asundexian (BAY2433334) · Drug: Apixaban matching placebo

  • Active comparator
    Apixaban

    Participants will receive apixaban and asundexian matching placebo.

    Drug: Apixaban · Drug: Asundexian matching placebo

Interventions

  • DrugAsundexianStudies of AsundexianAsundexian pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Once a day

  • 5 mg or 2.5 mg, twice a day, according to product label.

  • DrugAsundexian matching placebo

    Placebo to asundexian, once a day

  • DrugApixaban matching placebo

    Placebo to apixaban, twice a day

06

What researchers measure

Primary outcomes

  1. Number of Participants With Composite of Stroke or Systemic Embolism

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (this does not include myocardial infarction, thromboembolism of the pulmonary vasculature or venous thrombosis, e.g. pulmonary embolism or deep venous thrombosis).

    Time frame: Approximately 12 months

  2. Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding

    Assessment based on the (csHR), comparing asundexian with apixaban which is based on time to first event. ISTH Major Bleeding was defined as an event that meets at least one of the below criteria, based on the definition given by the ISTH (Schulman and Kearon 2005): * Fatal bleeding, and/or * Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular with compromised vision, pericardial, retroperitoneal, intra-articular, or intramuscular with compartment syndrome), and/or * Clinically overt\* bleeding associated with a recent (within 48 hours) decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared with the most recent hemoglobin value available before the event, and/or * Clinically overt\* bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. * Overt bleeding required the identification of the bleeding location and the hemoglobin drop and/or transfusion needed to be related to the bleeding.

    Time frame: Approximately 12 months

  3. Number of Participants With Composite of Stroke, Systemic Embolism, or ISTH Major Bleeding

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

    Time frame: Approximately 12 months

Secondary outcomes

  1. Number of Participants With Composite of Ischemic Stroke or Systemic Embolism

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. An ischemic stroke was defined as the rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\> 24 hours symptoms / signs) or imaging evidence of infarction that is not attributable to a non-ischemic cause (i.e. not associated with infection, tumor, seizure, severe metabolic disease).

    Time frame: Approximately 12 months

  2. Number of Participants With All-cause Mortality

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

    Time frame: Approximately 12 months

  3. Number of Participants With Ischemic Stroke

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. An ischemic stroke was defined as the rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\> 24 hours symptoms / signs) or imaging evidence of infarction that is not attributable to a non-ischemic cause (i.e. not associated with infection, tumor, seizure, severe metabolic disease).

    Time frame: Approximately 12 months

  4. Number of Participants With Cardiovascular (CV) Death

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. CV death included death due to stroke, myocardial infarction, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes or CV procedures. In addition, death due to non-traumatic cardiovascular hemorrhage will be included, e.g. non-stroke intracranial hemorrhage, non-procedural or non-traumatic vascular rupture (e.g. aortic aneurysm), or hemorrhage causing cardiac tamponade

    Time frame: Approximately 12 months

  5. Number of Participants With Composite of CV Death, Stroke, or Myocardial Infarction (MI)

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. The diagnosis of MI requires the combination of: * Presence of acute myocardial injury (changes in cardiac biomarkers) and * Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post mortem pathological findings irrespective of biomarker values.

    Time frame: Approximately 12 months

  6. Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Clinically relevant non-major bleeding was considered any sign or symptom of acute or sub-acute clinically overt bleeding that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria (based on criteria published by the EMA) (EMA 2014): * requiring medical or surgical treatment by a healthcare professional for bleeding * leading to hospitalization or increased level of care for bleeding * a change in antithrombotic therapy (including study intervention) for bleeding \*Overt bleeding required the identification of the bleeding location.

    Time frame: Approximately 12 months

  7. Number of Participants With Clinically Relevant Non-major Bleeding

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

    Time frame: Approximately 12 months

  8. Number of Participants With Hemorrhagic Stroke

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Hemorrhagic stroke was defined as an acute, atraumatic extravasation of blood into the brain parenchyma, intraventricular or subarachnoid space with associated neurological symptoms. This does not include microbleeds or hemorrhagic transformation of an ischemic stroke.

    Time frame: Approximately 12 months

  9. Number of Participants With Intracranial Hemorrhage

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

    Time frame: Approximately 12 months

  10. Number of Participants With Fatal Bleeding

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

    Time frame: Approximately 12 months

  11. Number of Participants With Minor Bleeding

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. All other overt bleeding episodes not meeting the criteria for ISTH major or clinically relevant non-major bleeding were classified as minor bleeding (for example, bleeding from a minor wound that does not prompt a treatment for the bleeding, for instance with surgical hemostasis, or epistaxis that does not require a medical treatment for bleeding or a change in antithrombotic therapy).

    Time frame: Approximately 12 months

  12. Number of Participants With Composite of Stroke, Systemic Embolism, ISTH Major Bleeding, or All-cause Mortality

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

    Time frame: Approximately 12 months

  13. Number of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality

    The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Critical bleeding was defined as symptomatic bleeding in either of the following critical locations (intracranial, intraspinal, pericardial, intra-articular, or retroperitoneal) or as intraocular bleeding with compromised vision or intramuscular bleeding with compartment syndrome.

    Time frame: Approximately 12 months

07

Results

Posted Dec 9, 2024

Participant flow

Study was conducted at 1035 study centers across in Asia, Europe, North America, South America, and Australia, between 05-Dec-2022 (first participant first visit) and 31-Jan-2024 (last participant last visit).

Participant flow — Overall Study
MilestoneAsundexianApixaban
Started73837374
Completed69017012
Not completed482362
Withdrew: Adverse event11790
Withdrew: Death5357
Withdrew: Lost to follow-up63
Withdrew: Other1815
Withdrew: Outcome event6436
Withdrew: Physician decision3319
Withdrew: Protocol-specified withdrawal criterion met22
Withdrew: Site terminated by sponsor1010
Withdrew: Study terminated by sponsor10
Withdrew: Withdrawal by subject178130

Outcome measures

PrimaryNumber of Participants With Composite of Stroke or Systemic Embolism

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (this does not include myocardial infarction, thromboembolism of the pulmonary vasculature or venous thrombosis, e.g. pulmonary embolism or deep venous thrombosis).

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Composite of Stroke or Systemic Embolism
ParticipantsAsundexianApixaban
Number of Participants With Composite of Stroke or Systemic Embolism9826
Statistical analysis
  • Asundexian vs Apixaban · Log Rank · p = <.0001 · Cox proportional hazard: 3.785 · 95% CI 2.457 to 5.833
  • Asundexian vs Apixaban · Gray's test · p = <.0001 · Fine-gray model: 3.790 · 95% CI 2.460 to 5.839
PrimaryNumber of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding

Assessment based on the (csHR), comparing asundexian with apixaban which is based on time to first event. ISTH Major Bleeding was defined as an event that meets at least one of the below criteria, based on the definition given by the ISTH (Schulman and Kearon 2005): * Fatal bleeding, and/or * Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular with compromised vision, pericardial, retroperitoneal, intra-articular, or intramuscular with compartment syndrome), and/or * Clinically overt\* bleeding associated with a recent (within 48 hours) decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared with the most recent hemoglobin value available before the event, and/or * Clinically overt\* bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. * Overt bleeding required the identification of the bleeding location and the hemoglobin drop and/or transfusion needed to be related to the bleeding.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding
ParticipantsAsundexianApixaban
Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding1753
Statistical analysis
  • Asundexian vs Apixaban · Log Rank · p = <.0001 · Fine-gray model: 0.319 · 95% CI 0.185 to 0.552
  • Asundexian vs Apixaban · Gray's test · p = <.0001 · Fine-gray model: 0.316 · 95% CI 0.182 to 0.547
PrimaryNumber of Participants With Composite of Stroke, Systemic Embolism, or ISTH Major Bleeding

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Composite of Stroke, Systemic Embolism, or ISTH Major Bleeding
ParticipantsAsundexianApixaban
Number of Participants With Composite of Stroke, Systemic Embolism, or ISTH Major Bleeding12075
Statistical analysis
  • Asundexian vs Apixaban · Log Rank · p = 0.0011 · Fine-gray model: 1.610 · 95% CI 1.207 to 2.149
  • Asundexian vs Apixaban · Gray's test · p = 0.0013 · Fine-gray model: 1.599 · 95% CI 1.197 to 2.134
SecondaryNumber of Participants With Composite of Ischemic Stroke or Systemic Embolism

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. An ischemic stroke was defined as the rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\> 24 hours symptoms / signs) or imaging evidence of infarction that is not attributable to a non-ischemic cause (i.e. not associated with infection, tumor, seizure, severe metabolic disease).

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Composite of Ischemic Stroke or Systemic Embolism
ParticipantsAsundexianApixaban
Number of Participants With Composite of Ischemic Stroke or Systemic Embolism9622
SecondaryNumber of Participants With All-cause Mortality

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With All-cause Mortality
ParticipantsAsundexianApixaban
Number of Participants With All-cause Mortality6071
SecondaryNumber of Participants With Ischemic Stroke

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. An ischemic stroke was defined as the rapid onset (or present on awakening) of a new focal neurological deficit with clinical (\> 24 hours symptoms / signs) or imaging evidence of infarction that is not attributable to a non-ischemic cause (i.e. not associated with infection, tumor, seizure, severe metabolic disease).

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Ischemic Stroke
ParticipantsAsundexianApixaban
Number of Participants With Ischemic Stroke8521
SecondaryNumber of Participants With Cardiovascular (CV) Death

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. CV death included death due to stroke, myocardial infarction, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes or CV procedures. In addition, death due to non-traumatic cardiovascular hemorrhage will be included, e.g. non-stroke intracranial hemorrhage, non-procedural or non-traumatic vascular rupture (e.g. aortic aneurysm), or hemorrhage causing cardiac tamponade

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Cardiovascular (CV) Death
ParticipantsAsundexianApixaban
Number of Participants With Cardiovascular (CV) Death4844
SecondaryNumber of Participants With Composite of CV Death, Stroke, or Myocardial Infarction (MI)

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. The diagnosis of MI requires the combination of: * Presence of acute myocardial injury (changes in cardiac biomarkers) and * Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post mortem pathological findings irrespective of biomarker values.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Composite of CV Death, Stroke, or Myocardial Infarction (MI)
ParticipantsAsundexianApixaban
Number of Participants With Composite of CV Death, Stroke, or Myocardial Infarction (MI)15577
SecondaryNumber of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Clinically relevant non-major bleeding was considered any sign or symptom of acute or sub-acute clinically overt bleeding that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria (based on criteria published by the EMA) (EMA 2014): * requiring medical or surgical treatment by a healthcare professional for bleeding * leading to hospitalization or increased level of care for bleeding * a change in antithrombotic therapy (including study intervention) for bleeding \*Overt bleeding required the identification of the bleeding location.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding
ParticipantsAsundexianApixaban
Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding83188
SecondaryNumber of Participants With Clinically Relevant Non-major Bleeding

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Non-major Bleeding
ParticipantsAsundexianApixaban
Number of Participants With Clinically Relevant Non-major Bleeding67140
SecondaryNumber of Participants With Hemorrhagic Stroke

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Hemorrhagic stroke was defined as an acute, atraumatic extravasation of blood into the brain parenchyma, intraventricular or subarachnoid space with associated neurological symptoms. This does not include microbleeds or hemorrhagic transformation of an ischemic stroke.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Hemorrhagic Stroke
ParticipantsAsundexianApixaban
Number of Participants With Hemorrhagic Stroke16
SecondaryNumber of Participants With Intracranial Hemorrhage

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Intracranial Hemorrhage
ParticipantsAsundexianApixaban
Number of Participants With Intracranial Hemorrhage318
SecondaryNumber of Participants With Fatal Bleeding

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Fatal Bleeding
ParticipantsAsundexianApixaban
Number of Participants With Fatal Bleeding04
SecondaryNumber of Participants With Minor Bleeding

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. All other overt bleeding episodes not meeting the criteria for ISTH major or clinically relevant non-major bleeding were classified as minor bleeding (for example, bleeding from a minor wound that does not prompt a treatment for the bleeding, for instance with surgical hemostasis, or epistaxis that does not require a medical treatment for bleeding or a change in antithrombotic therapy).

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Minor Bleeding
ParticipantsAsundexianApixaban
Number of Participants With Minor Bleeding187317
SecondaryNumber of Participants With Composite of Stroke, Systemic Embolism, ISTH Major Bleeding, or All-cause Mortality

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Composite of Stroke, Systemic Embolism, ISTH Major Bleeding, or All-cause Mortality
ParticipantsAsundexianApixaban
Number of Participants With Composite of Stroke, Systemic Embolism, ISTH Major Bleeding, or All-cause Mortality149101
SecondaryNumber of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality

The assessment was based on the cause-specific hazard ratio (csHR), comparing asundexian with apixaban which is based on time to first event. Critical bleeding was defined as symptomatic bleeding in either of the following critical locations (intracranial, intraspinal, pericardial, intra-articular, or retroperitoneal) or as intraocular bleeding with compromised vision or intramuscular bleeding with compartment syndrome.

Time frame:
Approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality
ParticipantsAsundexianApixaban
Number of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality5156

Adverse events

Collected over Approximately 12 months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asundexian73/7,373 (1%)582/7,373 (7.9%)467/7,373 (6.3%)
Apixaban85/7,364 (1.2%)599/7,364 (8.1%)455/7,364 (6.2%)
Most frequent serious events
Showing 10 of 500
Most frequent serious events
EventAsundexianApixaban
Atrial fibrillationCardiac disorders47/737371/7364
Cardiac failureCardiac disorders54/737362/7364
PneumoniaInfections and infestations22/737328/7364
Acute kidney injuryRenal and urinary disorders26/737312/7364
Cardiac failure acuteCardiac disorders18/737325/7364
Cardiac failure chronicCardiac disorders18/73738/7364
Cardiac failure congestiveCardiac disorders10/737314/7364
Urinary tract infectionInfections and infestations7/737313/7364
SyncopeNervous system disorders10/737312/7364
Chest painGeneral disorders11/737311/7364
Most frequent other events
Most frequent other events
EventAsundexianApixaban
DizzinessNervous system disorders132/7373113/7364
DiarrhoeaGastrointestinal disorders115/737372/7364
COVID-19Infections and infestations97/7373109/7364
NasopharyngitisInfections and infestations98/737389/7364
EpistaxisRespiratory, thoracic and mediastinal disorders50/737396/7364

Baseline characteristics

Full Analysis Set (FAS): All participants randomized to study intervention including participants who did not receive study intervention. N (number) =14830 Adjusted Full Analysis Set (aFAS): All participants in the Full Analysis Set excluding subjects randomized from one site in Japan. N=14810 Due to Good Clinical Practice violations, 20 participants from one site in Japan were excluded from all analyses.

Age, Continuous
Age, Continuous(Years)AsundexianApixabanTotal
Mean73.9 ± 7.773.9 ± 7.773.9 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)AsundexianApixabanTotal
Female265625585214
Male475948379596
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AsundexianApixabanTotal
Hispanic or Latino5335071040
Not Hispanic or Latino6774679313567
Unknown or Not Reported10895203
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AsundexianApixabanTotal
American Indian or Alaska Native448
Asian203520104045
Native Hawaiian or Other Pacific Islander9211
Black or African American8895183
White5216521110427
More than one race212849
Unknown or Not Reported424587
08

Study locations

1,069 sites
  • SEC Clinical Research
    Dothan, Alabama 36305, United States
  • Eastern Shore Research Institute, LLC | Fairhope, AL
    Fairhope, Alabama 36532, United States
  • Mobile Heart Specialists, PC
    Mobile, Alabama 36608, United States
  • University of South Alabama Medical Center
    Mobile, Alabama 36617, United States
  • Arkansas Cardiology | Little Rock
    Little Rock, Arkansas 72205, United States
  • Valley Clinical Trials, Inc. | Covina, CA
    Covina, California 91723, United States
  • Science 37
    Culver City, California 90230, United States
  • University of California, Irvine
    Irvine, California 92697, United States
  • VA Long Beach Healthcare System
    Long Beach, California 90822, United States
  • VA Greater Los Angeles Healthcare System | West Los Angeles VA Medical Center - Cardiology Department
    Los Angeles, California 90073-1003, United States
  • Radin Cardiovascular Medical Group
    Newport Beach, California 92663, United States
  • Amicis Research Center | Northridge, CA
    Northridge, California 91324, United States
  • Cottage Health | Santa Barbara Cottage Hospital - Cardiology Department
    Santa Barbara, California 93102, United States
  • NorthBay Clinical Research, LLC | Santa Rosa, CA
    Santa Rosa, California 95405, United States
  • The Lundquist Institute | Cardiology Department
    Torrance, California 90502-2004, United States
  • Harbor - UCLA Medical Center
    Torrance, California 90502, United States
  • Blue Coast Research Center, LLC
    Vista, California 92081, United States
  • Interventional Cardiology Medical Group | West Hills, CA
    West Hills, California 91307, United States
  • University of Colorado Hospital - Cardiology
    Aurora, Colorado 80045, United States
  • South Denver Cardiology Associates, PC
    Littleton, Colorado 80120, United States
  • Cardiology Associates of Fairfield County, P.C. | Stamford, CT
    Norwalk, Connecticut 06851, United States
  • Integrity Clinical Research | Florida Premier Cardiology
    Boynton Beach, Florida 33437, United States
  • Integrity Clinical Research | Cardiology Associates of South Florida
    Boynton Beach, Florida 33472, United States
  • Cardiovascular & Vein Center of Florida | Bradenton, FL
    Bradenton, Florida 34209, United States
  • Nova Clinical Research | Brandenton, FL
    Bradenton, Florida 34209, United States
  • Clearwater Cardiovascular Associates | Clearwater, FL
    Clearwater, Florida 33756, United States
  • Cardiology Consultants, PA
    Daytona Beach, Florida 32114, United States
  • Cardiology Associates Research Company
    Daytona Beach, Florida 32117, United States
  • Integrity Clinical Research | Heller Heart Health
    Delray Beach, Florida 33446, United States
  • North Florida Foundation For Research And Education | Veterans Benefits Administration
    Gainesville, Florida 32608, United States
  • Indago Research and Health Center | Hialeah, FL
    Hialeah, Florida 33012, United States
  • Encore Research Group | Nature Coast Clinical Research - Inverness
    Inverness, Florida 34452, United States
  • University of Florida - Jacksonville
    Jacksonville, Florida 32209, United States
  • Heart Vein & Vascular | Longwood, FL
    Longwood, Florida 32779, United States
  • Life Spring Research | Miami, FL
    Miami, Florida 33130, United States
  • Southwest Florida Research | Naples, FL
    Naples, Florida 34102-8143, United States
  • Advanced Research for Health Improvement, LLC | Naples, FL
    Naples, Florida 34102, United States
  • Cardiology Partners Clinical Research Institute | Palm Beach Gardens Office
    Palm Beach Gardens, Florida 33410, United States
  • Baptist Heart and Vascular/Cardiology Consultants
    Pensacola, Florida 32503, United States
  • Peace River Cardiovascular Center | Port Charlotte, FL
    Port Charlotte, Florida 33592, United States
  • Encore Research Group | St. Johns Center for Clinical Research
    Saint Augustine, Florida 32081, United States
  • East Coast Institute for Research | St. Augustine, FL
    Saint Augustine, Florida 32086, United States
  • Cardiovascular Center of Sarasota Foundation for Research and Education | Sarasota, FL
    Sarasota, Florida 34239, United States
  • Cardiology Partners Clinical Research Institute | Wellington Office
    Wellington, Florida 33449, United States
  • St. Mary's Medical Center | West Palm Beach - Neurology Department
    West Palm Beach, Florida 33407-2495, United States
  • Morehouse School of Medicine | Clinical Research Centre
    Atlanta, Georgia 30303-3031, United States
  • NSC Cardiology | Johns Creek, GA
    Cumming, Georgia 30041, United States
  • Alta Pharmaceutical Research Center, LLC
    Peachtree Corners, Georgia 30092, United States
  • Atlanta Heart Specialists, LLC
    Tucker, Georgia 30084, United States
  • St. Luke's Health System | St. Luke's Clinic - Idaho Cardiology Associates
    Meridian, Idaho 83642, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Northshore Medical Center
    Glenview, Illinois 60026, United States
  • Affinity Health Research Institute | Oak Brook, IL
    Oak Brook, Illinois 60523, United States
  • Midwest Cardiovascular Research and Education Foundation | Elkhart, IN
    Elkhart, Indiana 46514, United States
  • Cardiovascular Research of Northwest Indiana, LLC. | Munster, IN
    Hammond, Indiana 46320, United States
  • IU Health Physicians Cardiology
    Indianapolis, Indiana 46202, United States
  • Reid Physician Associates | Cardiology Department
    Richmond, Indiana 47374, United States
  • Accellacare | Ames, IA
    Ames, Iowa 50010, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Kansas Nephrology Physicians, PA
    Wichita, Kansas 67226, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • Baptist Health Medical Group - Louisville Cardiology
    Louisville, Kentucky 40207, United States
  • Research Integrity, LLC
    Owensboro, Kentucky 42303, United States
  • Cambridge Medical Trials
    Alexandria, Louisiana 71301, United States
  • Ochsner Clinic Foundation
    Baton Rouge, Louisiana 70836, United States
  • Cardiovascular Associates Research, LLC
    Covington, Louisiana 70433, United States
  • Ochsner Medical Center - New Orleans
    New Orleans, Louisiana 70121, United States
  • Louisiana Heart Center Research - Slidell
    Slidell, Louisiana 70458, United States
  • Northeast Cardiology Associates
    Bangor, Maine 04401, United States
  • MaineHealth Maine Medical Center | Maine Medical Partners Cardiology
    Scarborough, Maine 04039, United States
  • LifeBridge Health | Sinai Hospital - Platelet and Thrombosis Research Department
    Baltimore, Maryland 21215, United States
  • Spectrum Clinical Research | Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States
  • Johns Hopkins Hospital/Health System
    Baltimore, Maryland 21287, United States
  • Johns Hopkins University School of Medicine | CAPRES
    Columbia, Maryland 21044, United States
  • Anderson Medical Group and Cardiology | Anderson Medical Research, LLC
    Fort Washington, Maryland 20744, United States
  • Adventist HealthCare | White Oak Medical Center
    Silver Spring, Maryland 20904, United States
  • McLaren Health Care | McLaren Bay Region - Research Department
    Bay City, Michigan 48708, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • AA Medical Research Center | Flint, MI
    Flint, Michigan 48504, United States
  • Sparrow Clinical Research Institute | Sparrow Hospital - Clinical Research Department
    Lansing, Michigan 48912, United States
  • M Health Fairview
    Maplewood, Minnesota 55109, United States
  • Veterans Benefits Administration | Minneapolis VA Medical Center - Cardiology Department
    Minneapolis, Minnesota 55417, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Minneapolis Heart Institute
    Saint Paul, Minnesota 55102, United States
  • Jackson Heart Clinic | Jackson, MS
    Jackson, Mississippi 39216, United States
  • Cardiology Associates Research, LLC
    Tupelo, Mississippi 38801, United States
  • St. Louis Heart & Vascular, PC
    Saint Louis, Missouri 63136, United States
  • CHI Health Clinic Heart Institute - Grand Island
    Grand Island, Nebraska 68803, United States
  • Advanced Heart Care, LLC | Bridgewater, NJ
    Bridgewater, New Jersey 08807, United States
  • NJ Heart | Linden, NJ
    Linden, New Jersey 07036, United States
  • Garden State Heart Care
    Manalapan, New Jersey 07726, United States
  • Inspira Medical Centers | Clinical Research Office
    Mullica Hill, New Jersey 08062, United States
  • The Valley Hospital, Inc.
    Ridgewood, New Jersey 07450, United States
  • Cooper Specialty Care at Voorhees
    Voorhees, New Jersey 08043, United States
  • IMA Clinical Research | Warren, NJ
    Warren, New Jersey 07059, United States
  • Circuit Clinical/Crystal Run
    Middletown, New York 10941, United States
  • NYU Langone Health | NYU Langone Medical Associates Chelsea - Cardiovascular Research
    New York, New York 10001, United States
  • Division of Cardiovascular Research at Peconic Bay Med Ctr
    Riverhead, New York 11901, United States
  • Great Lakes Medical Research | Westfield, NY
    Westfield, New York 14787, United States
  • University of North Carolina at Chapel Hill | Cardiology Department
    Chapel Hill, North Carolina 27514, United States

Showing the first 100 of 1,069 sites across 38 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jan 2024, 13 months.

Results were first posted in Dec 2024, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 8, 2022
StartActual
Dec 5, 2022
Primary completionActual
Jan 31, 2024
CompletionActual
Jan 31, 2024
Results first posted
Dec 9, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05643573
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Dec 5, 2022
Primary completion
Jan 31, 2024
Completion
Jan 31, 2024
Results posted
Dec 9, 2024
Last update
Dec 9, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asundexian

Start the discussion